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Coronavirus Disease 2019 (COVID-19)
Evaluating and Testing Persons for Coronavirus
Disease 2019 (COVID-19)
CDC has updated its guidance on what specimens to collect when testing for COVID-19. The latest guidance is
available online at Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19).
Updated March 4, 2020
Limited information is available to characterize the spectrum of clinical illness associated with coronavirus disease 2019
(COVID-19). No vaccine or specific treatment for COVID-19 is available; care is supportive.
The CDC clinical criteria for considering testing for COVID-19 have been developed based on what is known about COVID-
19 and are subject to change as additional information becomes available.
Summary of Recent Changes
Revisions were made on March 9, 2020, to reflect the following:
Reorganized the Criteria to Guide Evaluation and Laboratory Testing for COVID-19 section
Revisions were made on March 4, 2020, to reflect the following:
Criteria for evaluation of persons for testing for COVID-19 were expanded to include a wider group of
symptomatic patients.
CDC Health Advisory
Update and Interim Guidance on Outbreak of Coronavirus Disease 2019 (COVID-19)
CDC continues to closely monitor an outbreak of respiratory illness caused by COVID-19 that was initially detected in
Wuhan City, Hubei Province, China. This HAN Update provides a situational update and guidance to state and local
health departments and health care providers.
Criteria to Guide Evaluation and Laboratory Testing for
COVID-19
Clinicians should continue to work with their local and state health departments to coordinate testing through public
health laboratories. In addition, COVID-19 diagnostic testing, authorized by the Food and Drug Administration under an
Emergency Use Authorization (EUA), is becoming available in clinical laboratories. This additional testing capacity will
allow clinicians to consider COVID-19 testing for a wider group of symptomatic patients.
Clinicians should use their judgment to determine if a patient has signs and symptoms compatible with COVID-19 and
whether the patient should be tested. Most patients with confirmed COVID-19 have developed fever  and/or symptoms
of acute respiratory illness (e.g., cough, difficulty breathing). Priorities for testing may include:
1. Hospitalized patients who have signs and symptoms compatible with COVID-19 in order to inform decisions related
to infection control.
2. Other symptomatic individuals such as, older adults and individuals with chronic medical conditions and/or an
immunocompromised state that may put them at higher risk for poor outcomes (e.g., diabetes, heart disease,
receiving immunosuppressive medications, chronic lung disease, chronic kidney disease).
3. Any persons including healthcare personnel , who within 14 days of symptom onset had close contact  with a
suspect or laboratory-confirmed  COVID-19 patient, or who have a history of travel from affected geographic areas
(see below) within 14 days of their symptom onset.
There are epidemiologic factors that may also help guide decisions about COVID-19 testing. Documented COVID-19
infections in a jurisdiction and known community transmission may contribute to an epidemiologic risk assessment to
inform testing decisions. Clinicians are strongly encouraged to test for other causes of respiratory illness (e.g., influenza).
Mildly ill patients should be encouraged to stay home and contact their healthcare provider by phone for guidance about
clinical management. Patients who have severe symptoms, such as difficulty breathing, should seek care immediately.
Older patients and individuals who have underlying medical conditions or are immunocompromised should contact their
physician early in the course of even mild illness.
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Contact your local or state health department
Healthcare providers should immediately notify their local  or state  health department in the event
of the identification of a PUI for COVID-19. When working with your local or state health department check
their available hours.
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Recommendations for Reporting, Testing, and Specimen
Collection
Updated February 28, 2020
Clinicians should immediately implement recommended infection prevention and control practices if a patient is
suspected of having COVID-19. They should also notify infection control personnel at their healthcare facility and their
state or local health department if a patient is classified as a PUI for COVID-19. State health departments that have
identified a PUI or a laboratory-confirmed case should complete a PUI and Case Report form through the processes
identified on CDC’s Coronavirus Disease 2019 website. State and local health departments can contact CDC’s Emergency
Operations Center (EOC) at 770-488-7100 for assistance with obtaining, storing, and shipping appropriate specimens to
CDC for testing, including after hours or on weekends or holidays.
For initial diagnostic testing for COVID-19, CDC recommends collecting and testing upper respiratory tract specimens
(nasopharyngeal swab). CDC also recommends testing lower respiratory tract specimens, if available. For patients who
develop a productive cough, sputum should be collected and tested for COVID-19. The induction of sputum is not
recommended. For patients for whom it is clinically indicated (e.g., those receiving invasive mechanical ventilation), a
lower respiratory tract aspirate or bronchoalveolar lavage sample should be collected and tested as a lower respiratory
tract specimen. Specimens should be collected as soon as possible once a PUI is identified, regardless of the time of
symptom onset. See Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Patients Under
Investigation (PUIs) for COVID-19 and Biosafety FAQs for handling and processing specimens from suspected cases and
PUIs.
Footnotes
Fever may be subjective or confirmed
For healthcare personnel, testing may be considered if there has been exposure to a person with suspected COVID-19
without laboratory confirmation. Because of their often extensive and close contact with vulnerable patients in
healthcare settings, even mild signs and symptoms (e.g., sore throat) of COVID-19 should be evaluated among potentially
exposed healthcare personnel. Additional information is available in CDC’s Interim U.S. Guidance for Risk Assessment and
Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting to Patients with
Coronavirus Disease 2019 (COVID-19).
Close contact is defined as—
a) being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period of time; close contact can
occur while caring for, living with, visiting, or sharing a healthcare waiting area or room with a COVID-19 case
– or –
b) having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on)
If such contact occurs while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves,
NIOSH-certified disposable N95 respirator, eye protection), criteria for PUI consideration are met.
Additional information is available in CDC’s updated Interim Infection Prevention and Control Recommendations for
Patients with Confirmed COVID-19 or Persons Under Investigation for COVID-19 in Healthcare Settings.
Data to inform the definition of close contact are limited. Considerations when assessing close contact include the
duration of exposure (e.g., longer exposure time likely increases exposure risk) and the clinical symptoms of the person
with COVID-19 (e.g., coughing likely increases exposure risk as does exposure to a severely ill patient). Special
consideration should be given to healthcare personnel exposed in healthcare settings as described in CDC’s Interim
U.S. Guidance for Risk Assessment and Public Health Management of Healthcare Personnel with Potential Exposure in
a Healthcare Setting to Patients with COVID-19.
Documentation of laboratory-confirmation of COVID-19 may not be possible for travelers or persons caring for COVID-19
patients in other countries.
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Affected areas are defined as geographic regions where sustained community transmission has been identified. For a list
of relevant affected areas, see CDC’s Coronavirus Disease 2019 Information for Travel.
Additional Resources:
State health department after-hours contact list
Directory of Local Health Departments
World Health Organization (WHO) Coronavirus
WHO guidance on clinical management of severe acute respiratory infection when COVID-19 is suspected
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